1 AN INTERNATIONAL UROGYNECOLOGICAL ASSOCIATION (IUGA)/ INTERNATIONAL 2 CONTINENCE SOCIETY (ICS) JOINT REPORT ON THE TERMINOLOGY FOR REPORTING 3 **OUTCOMES OF SURGICAL PROCEDURES FOR PELVIC ORGAN PROLAPSE** 4 Version 17 5 Philip Toozs-Hobson, Robert Freeman, Stavros Athanasiou, Bernard Haylen, Matthew 6 Barber, Steven Swift, Christopher Maher, Kristene Whitmore, Gamal Ghoneim, Dirk de 7 Ridder. Terminology Committee (IUGA) and Standardization Steering Committee (ICS) Joint 8 Working Group on Terminology of Surgical Procedures for Pelvic Organ Prolapse 9 10 This document is being published simultaneously in Neurourology and Urodynamics (NAU) 11 and the International Urogynaecology Journal (IUJ), the respective journals of the sponsoring 12 organisations, the international continence society (ICS) and the international 13 Urogynaecological Association (IUGA) in XXXXX

14 Standardisation and terminology committee IUGA working group members: Bernard T.

15 Haylen, Stephen E.Swift, Stavros Athanasiou, Matthew Barber, Gamal Ghoneim

16 Standardisation and Terminology Committee (ICS) working group members: Robert. M

17 Freeman, Dirk de Ridder, Christopher Maher, Kristene Whitmore, Philip M. Toozs-Hobson.

18

19 <u>Authors</u>

- 20 Philip Toozs-Hobson, Birmingham Women's Hospital, Birmingham. United Kingdom
- 21 Robert Freeman, Plymouth Hospitals NHS Trust, Plymouth. United Kingdom
- 22 Stavros Athanasiou, Alexandra Hospital, University of Athens, Athens. Greece.
- 23 Bernard Haylen, University of New South Wales, Sydney. N.S.W. Australia.
- 24 Matthew Barber, Cleveland Clinic, Cleveland. Ohio. U.S.A

25	Steven Swift, Medical University of South Carolina, Charleston. South Carolina. U.S.A.			
26	Christopher Maher, Wesley Hospital, Brisbane. Queensland. Australia			
27	Kristene Whitmore, Drexel University College of Medicine, Philadelphia. Pensilvania. USA			
28	Gamal Ghoneim University of California, Irvine. California. U.S.A.			
29	Dirk de Ridder, University Hospital, UZ Leuven. Belgium			
30				
31				
32				
33	Correspondence to: Mr Philip Toozs-Hobson, Birmingham Women's Hospital, Birmingham.			
34	B15 2TG UK philip.toozs-hobson@bwhct.nhs.uk			
35				
36				
37				
38				
39	Abstract			

40 *Introduction and hypothesis.* A formal terminology has yet to be developed for reporting the
41 outcomes for surgery for pelvic organ prolapse.

42 *Methods* This report on the above terminology combines the input of members of the 43 Terminology and Standardisations Committees of 2 International Organisations, the 44 International Continence Society (ICS) and the International Urogynecology Association 45 (IUGA) and a joint Working Group on this topic, assisted by many expert external referees. 46 An extensive process involved 17 versions and 6 collations prior to open to review on both 47 IUGA and ICS websites to allow members 6 weeks to submit comments and 48 recommendations which have enabled appropriate revisions. 49 Results. A terminology report to standardise reporting of outcomes from pelvic organ 50 prolapse has been developed. The report concentrates on the definitions of outcome in 51 primary and repeat surgery. In addition emphasis is made regarding patient reported 52 outcomes which will enable researchers to report on the clinically meaningful results of 53 surgery. 54 Conclusions A consensus based method for standardising terminology for reporting 55 outcome measures of prolapse surgery has been developed as an aid to clinicians working in 56 this area of research. 57 58 59 Key Words 60 Terminology, outcomes, surgical procedures, pelvic organ prolapsed, female pelvic floor 61 dysfunction. 62 63 64 Preface 65 66 The aim of this report is to present a standardised terminology for the definitions of surgery 67 and propose a structure for reporting the outcomes of surgical procedures for pelvic organ 68 prolapse (POP). The document does not define success and failure, but outlines the 69 structure that is recommended for reporting outcomes of surgical trials involving POP. The 70 report includes patient-reported, subjective and objective outcomes and should be used in 71 conjunction with the IUGA/ICS reports on the terminology for female pelvic floor

72 dysfunction⁷ and the classification of the complications related to the insertion of prostheses

73 and grafts and native tissue $\frac{1}{7}\frac{2}{7}\frac{3}{7}$.

74 The first aim is to standardise the terminology used in this classification.

The word outcome is defined in the Oxford English dictionary⁴ as [N] the way a thing
 turns out; a consequence: *it is the outcome of the vote that counts*

77

78 Introduction

79 Whilst recommendations for reporting outcomes of surgery for stress urinary incontinence

80 have been reported⁵,⁶, few exist for surgery of pelvic organ prolapse (POP).

81

82 The first attempt to quantify re-operation rates in women undergoing prolapse surgery was by Olsen et al⁷. This paper assessed both incontinence and prolapse surgery and the lifetime 83 84 risk of requiring surgery was 11% with 29% requiring further surgery. If prolapse surgery alone was considered the lifetime risk was 6.7%. The definition of repeat surgery was any 85 86 operation for prolapse or urinary incontinence following an index procedure, often some 87 years previously. Whilst this paper is still commonly quoted, the failure to adjust for both 88 time and variation in operative site, reduces the usefulness of the conclusions and might be 89 misleading with regards to the true failure rate of POP surgery. This observation is borne out, when the same cohort was reviewed 10 years later with the authors⁸ quoting a 17% re-90 91 operation rate. On further analysis of same compartment recurrence i.e. repeat anterior repair, the re-operation rate was significantly lower at 4.6%⁹. 92

More recently several investigators have looked specifically at the issue of site specific
 recurrence with re-operation rates ranging from 2.8-9.7%^{,10,11,12}

In 2001 Weber et al¹³ reported a 58 to 70% failure rate for anterior colporraphy. This study has been subject to further analysis as the definitions of objective success and failure were based on POPQ changes of small magnitude. It has been shown that when more clinically relevant criteria for success are used (i.e. anatomic recurrence beyond the hymen, symptomatic recurrence and re-operation), that outcome is considerably better with only 10% of subjects developing anatomic recurrence beyond the hymen, 5% developing symptomatic recurrence and re-operations less than 1% (at 23 months follow-up)¹⁴.

102 A recent article looking at vault suspension suggested that re-operation rates after POP 103 surgery which includes suspension of the apex are 1.3 to 3.9% at 17 to 32 months 104 depending upon the type of vault suspension¹⁵. These data become more useful in terms of 105 site and timescales.

106

107 The lack of subjective/patient-reported outcome measures in many studies was highlighted 108 in a systematic review on mesh repairs commissioned by the National Institute for Clinical 109 Excellence (NICE)¹⁶ in the UK¹⁷. As a consequence of this and the uncertainty following 110 further consideration of the Olsen and Weber^{7,13} data, there is clearly a need for 111 standardisation of outcome measures for pelvic organ prolapse surgery .

112

113 New Definitions

114

115 It is understood that there is close interaction among all three commonly defined 116 compartments (apical/ vault, anterior and posterior) when discussing pelvic organ support 117 or prolapse. However, for ease of use the definitions are limited to 'primary' or 'recurrence 118 at specific sites' defined as apical/vault, anterior and posterior.

119	As our understanding of how these various compartments interact improves, the			
120	definitions of 'primary prolapse surgery/different site' and 'repeat surgery/same site' will			
121	evolve.			
122	The nomenclature is proposed as standardised terminology for surgical trials and audit.			
123				
124	Primary surgery for POP is the first procedure required for the treatment of POP in any			
125	compartment			
126				
127	Further surgery ^a This gives a global figure for the number of subsequent procedures the			
128	patient undergoes directly or indirectly relating to the primary surgery. This is subdivided			
129	into:			
130	a. Primary prolapse surgery/different site. A prolapse procedure in a new			
131	site/compartment following previous surgery in a different compartment (e.g.			
132	anterior repair following previous posterior repair).			
133				
134	b. Repeat surgery: is a repeat operation for prolapse arising from the same site.			
135	Where combinations of procedures arise, e.g. new anterior repair plus further posterior			
136	repair these should be reported separately i.e. repeat posterior repair and primary anterior			
137	repair.			
138	c. Surgery for Complications: e.g. mesh exposure or extrusion or pain or patient			
139	compromise e.g. haemorrhage (see complications section)			
140	d. Surgery for non-prolapse related conditions e.g. subsequent surgery for stress			
141	urinary incontinence or faecal incontinence.			

^a Further surgery should not be interpreted as a measure or failure as the definitions of success and failure will be defined within the context of the individual study

142

143 <u>Reporting Outcomes</u>

144

One of the major difficulties in reporting the results of prolapse surgery is that, unlike most other surgeries, there is a range of outcomes which are not reported in a consistent manner; this makes assessment of procedures difficult.

The International Consultation on Incontinence (ICI) has already suggested that POP and Urinary Incontinence surgery should report subjective, objective and quality of life outcomes5. The importance of this is that there are then a number of measures that can be used to generate useful information to benchmark practice for and against a particular procedure and also inform patients about potential outcomes.

153

154 In terms of clinical research studies, entry criteria, design, methodology, power and absence 155 of bias assessment are important in allowing the reader to assess the reliability of the 156 findings with regards to changing practice. There are already accepted standards for study 157 design and reporting of RCT's including (but not limited to) the CONSORT^b guidelines¹⁸, 158 Moose¹⁹ and STARD²⁰. Researchers should quote which standard they adopt and reference 159 accordingly.

^b CONSORT requires detailed information provided by authors to reviewers. This is not always possible because many authors fail to provide complete descriptions of critical information. The frustration of trying to accurately evaluate systematic reviews and metaanalyses has led to a new instrument named PRISMA, which stands for 'Preferred Reporting Items for Systematic Reviews and Meta-Analyses'. The aim of the PRISMA statement is to give authors an evidence-based minimum set of items to improve the reporting of systematic reviews and meta-analyses in POP issues.

PRISMA statement. Available at: http://www.prisma-statement. org/.

161 Until now few studies have provided data on patients' pre-operative goals and expectations ^{21,22,23,24}. These might have significant advantages over objective measures of outcome. 162 With this in mind goals should be reported using SMART criteria²⁵. This acronym stands for:-163 164 Specific e.g. defining goal (for POP, absence of bulge) 165 166 Measureable e.g. validated symptom scale (e.g. POP-SS or ICIQ-VS or EPAQ) or objective 167 measure e.g. POPQ 168 Appropriate e.g. relevant to improving patient lifestyle 169 Realistic e.g. achievable by treatment 170 Timely e.g. at six months/2 years 171 172 So examples for POP surgery would be:-173 (i) The absence of bother from a vaginal bulge as defined using the EPAQ score at 2

174 years. This is specific in absence of a bulge, measurable in terms of a binary
175 question, appropriate as relevant to the surgery, realistic as a surgical outcome and
176 timely at 2 years

177

(ii) Physical objective: Resumed exercise as defined by resuming low impact excercise
without recurrence of bothersome/limiting symptoms by 6 months. Likewise this is specific
in terms of defined outcome (resumed exercise), again measurable with a binary question,
appropriate and realistic with a timeline.

182

(iii) Resumption of normal bowel movements as defined by ability to evacuate withoutdigitation maintained at 2 years post surgery. Again this is a specific target ability to

185	evacuate bowels without digitation, which is realistic and appropriate and measureable with					
186	a binary question or bowel questionnaire with an appropriate timeline					
187						
188						
189						
190						
191	Outcomes					
192						
193	The following data should be reported following surgical treatment of pelvic organ prolapse.					
194 1.	Perioperative data: Blood loss (mls) and or haemoglobin change, operating time,					
195	inpatient stay, return to usual activities of daily living, complications (see below).					
196						
197	2. <u>Patient reported outcomes</u> : The primary reported outcome would be the absence of a					
198	bulge, e.g. as determined from a validated symptom scale.					
199	3. <u>Satisfaction</u> : Using qualitative measures such as a patient defined measure or a validated					
200	instrument					
201	4. Quality of life Using an appropriately validated questionnaire for the population being					
202	studied. (see ICI and ICIQ) ²⁶					
203	5. <u>Objective outcomes</u> (e.g. POPQ or simplified POPQ) ^{27,28,29}					
204	a. These should be tabulated with percentages achieving each level to again allow					
205	studies to compare results as definitions of success will vary from study to study.					
206						
207						
208	6. <u>Further surgery</u>					

- 209
- a. As per definitions above

210

7. Economic evaluation/cost analysis. See below.

212

211

- 213 8. <u>Complications</u> Complications specifically related to mesh and native tissue should be 214 reported as per the IUGA/ICS classification of complications directly related to the
- 215 insertion of prostheses and grafts and native tissue in female pelvic floor surgery ^{(2).}
- 216
- 217

218 **Patient reported outcomes (Subjective outcomes).**

- The primary outcome should be subjective and would usually be the absence of a
 bulge. This can be regarded as a 'subjective cure³⁰. This can be recorded as part of a
 symptom scale up to date details of validated questionnaires can be found on the <u>ICI</u>
 website.
- To make this fit with the SMART criteria this should be defined at a specific time interval and classified on a 7-point Likert scale (much better, slightly better, no change, slightly worse, much worse) e.g. the patient global impression of improvement (PGI-I)³¹ (see below).
- 227
- <u>Satisfaction.</u>
- The patient global impression of improvement (PGI-I)³¹ should be reported as a 7 point scale.
- 231 <u>Qualitative assessment</u>. This could include the acronym EGGS³² or an assessment of 232 goal achievement. Again these should be SMART. The number of pre-specified goals

233	should be recorded and the number achieved post-operatively also reported for			
234	responsiveness and reliability of goal achievement ²¹ .			
235				
236				
237	• <u>Secondary outcomes</u> should include an assessment of the following:			
238	Other symptoms known to be associated with prolapse e.g.			
239				
240	Backache			
241				
242	LUTS e.g. overactive bladder, stress urinary incontinence (either pre-existing			
243	or de-novo), voiding difficulty.			
244				
245	Bowel dysfunction e.g. obstructed defecation, feeling of incomplete			
246	emptying, constipation and digitation.			
247				
248	Sexual dysfunction e.g. dyspareunia, loss of libido, abstinence due to prolapse			
249	symptoms, change in sexual satisfaction.			
250				
251	De novo/new onset symptoms e.g. LUTS, sexual dysfunction, pain, bowel			
252	dysfunction.			
253				
254	Objective outcomes. These should include pre- and post-operative assessment with a			
255	timeline for changes. The recommended method of the ICS and IUGA is the POP- Q^{33} or			
256	simplified POP-Q ²⁹ .			

Authors should report the site of the leading edge of the prolapse in a table form giving the percentages of patients achieving different points. This will then allow comparison of objective results between studies^c. Alternatively, the Weber et al classification³⁴ can be used.

261

262

263 **Quality of Life**. Appropriate and fully validated quality of life instruments should be used 264 such to cover prolapse, urinary, bowel and sexual function²⁶. New questionnaires can be 265 included when they have demonstrated good psychometric properties (i.e. validity, 266 reliability and responsiveness) in women with pelvic organ prolapse

267

268

269 **<u>Timelines for Further Surgery</u>**

This should be described using the classification above and described chronologically as below. Readers should note these timescales are different to those in the mesh complications report (1) i.e.

- 273 Very early (up to 3 months)
- 274 Early (up to one year)
- 275 Intermediate (12-36 months)
- 276 Late (3-5 years)
- 277 Very late (greater than 5 years)

278

^c With the advent of electronic publishing authors may be able to include several tables outlining this over and above the details included in any paper publication

280 Cost Analysis

Despite considerable cost, a sparsity of cost-effectiveness data exist on prolapse surgery.
Investigators are encouraged to include economic analyses in their studies whenever possible.

284 Economic evaluation techniques provide systematic ways to compare the costs and 285 consequences of clinical and other health sector interventions. Cost-utility analysis (CUA)—a form of cost-effectiveness analysis (CEA)—is by far the most commonly-used and requires 286 287 one to quantify the effects of interventions on morbidity and mortality. In a CUA, benefits 288 are measured in physical units (e.g., quality-adjusted life-years (QALYs) and costs are monetized to create a ratio of costs to consequences (e.g., "cost per QALY saved"). QALY's 289 290 are usually calculated through a validated general quality of life outcome such as SF-36 or 291 EQ-5D or by other measures of utility like the standard gamble or time-trade off technique . 292 These ratios enable one to compare competing interventions on the basis of the cost at which 293 they create improvements in health-related quality-of-life. CUA is particularly useful when 294 two interventions create different health and longevity profiles (e.g., Drug A results in 295 superior clinical results and also greater costs than Drug B). If it is known that the health 296 consequences of two interventions are clinically equivalent in QoL outcomes, a cost-297 minimisation analysis (CMA) as performed above is an appropriate analytical approach.

298

Economic analyses should attempt to quantify both direct and indirect costs. Direct medical costs should include personnel costs/time (physician, nurse, technician), diagnostic and laboratory tests, hospital costs, treatment costs (drugs, operating room time, etc.), treatment of side effects, and outpatient visits. Indirect costs are often more difficult to quantify but should include e.g. loss of productivity, time lost from work, loss of service to family and community, and premature mortality. In economic evaluations, it is important to consider the

government, society) will have significant influence on which costs should be included in the				
analysis.				
Complications of surgery				
These need to be classified as intra-operative, post operative and generic.				
Intra-operative				
Visceral injury (bladder/bowel)				
Nerve injury				
• Unscheduled additional procedure (eg oopherectomy at vaginal hysterectomy for				
whatever reason e.g. haemorrhage)				
haemorrhage				
Post operative				
Urinary retention				
De novo urinary incontinence				
• Fistula				
• Haematoma				
Dyspareunia				
Urinary tract infection				
Constipation/bowel dysfunction				

perspective of the evaluation, as the perspective (e.g., patients, hospital, third-party payer,

329	Pelvic infection/abscess
330	• Pain
331	• Sinus
332	Haemorrhage
333	DVT/ PE
334	
335	Generic
336	
337	The Dindo classification ³⁵ , consists of 4 severity grades of complications. This has been
338	modified to include a fifth category ³⁶
339	
340	The Clavien-Dindo Complication Classification:
341	Grade I: requires no treatment
342	Grade II: requires drug therapy
343	Grade III: requires a procedure or intervention (a: in local; b: general anesthesia)
344	Grade IV: IC/ICU organ or system dysfunction (a: single organ; b: multi-organ
345	dysfunction)
346	Grade V: death
347	
348	Major complications should be recorded and include:
349	Haemorrhage requiring blood transfusion
350	• Return to theatre/Operating room within 72 hours of surgery, return to hospital
351	within 30 days for procedure related event, return to theatre within 30 days for
352	procedure related event.

Severe infection requiring prolonged admission or additional intravenous antibiotics
 354

Long- term complications causing disruption to quality of life and/or impairment of
 normal physical or mental functioning

357

358

359 Pain is classified separately and dealt with in a separate report for the classification of 360 prostheses (mesh, implants, tapes) complications2. As in the native tissue classification3 361 there is a categorical description of complications with a numerical value referring to the 362 description and an alphabetical classification describing symptoms. This classification has a 363 C value for category, T for time and S for site. Additional information on pain may include 364 permanent or temporary and severity as measured by impact on quality of life (which may 365 be descriptive or QoL based) and treatment required (e.g. simple oral analgesia, compound 366 analgesia, opiates, referral and management by pain team)

367

368

369

370

371

372 **DISCUSSION**

373

New surgical procedures for POP reconstructive surgery have evolved dramatically over the last 15 years suggesting that the perceived dissatisfaction with conventional/traditional surgery as expressed by White³⁷ at the turn of the twentieth century persists. This perception is based on clinical experience and reports of anatomical failure and reoperation^{7,13}. As the interpretations of these findings have been questioned by more recent studies, there is an urgent need for a standardised method of reporting surgical outcomes so that appropriate success and failure rates can be reported.

381 This document has been borne from the recognition that contemporary practice lacks 382 sufficient reproducible evidence to help clinicians translate findings into clinical practice and 383 enable patients to be aware of likely outcomes.

The assessment of prolapse surgery has been subject to a number of limitations. Firstly and perhaps most importantly is the quality of studies with most being case series with very few properly constructed (and powered) RCT's. As a result the quality of the available evidence is lacking. The emphasis then lies within systematic reviews and meta-analyses which may be less robust due to the lack of good quality data.

389 It can be argued that new procedures have been introduced despite a lack of evidence of 390 poor outcomes from traditional/conventional surgery. Such procedures are often 391 introduced in a less regulated manner than for new drug therapies³⁸.

This report sets out to provide a framework through which researchers and clinicians canstandardise reporting and allow results to become more transferable.

History has taught us that surgical complications (particularly in the case of implants) may be long term and researchers should be encouraged to revisit early (e.g. 1 year) results and include long term data of 5-10 years.

The Austrian and Finnish experiences with mid-urethral slings e.g. TVT have demonstrated that in addition to properly constructed prospective trials that there is a moral and ethical responsibility for users of advanced techniques such as those employing implants, to contribute to clinical governance and audit through local, regional or national databases. 401

402

403

404 Summary of recommendations for POP surgical outcomes

405 In all surgical trials of POP surgery authors should report:

406 Methods, CONSORT and type of surgery (primary or further using the agreed 407 definitions). The table below also outlines what should be reported in audit of clinical 408 practice and surgical trials. In addition researchers should give a commitment in the 409 original trial design and at publication of early results, to publish longer term data at a 410 minimum of 5 years.

411

	Clinical	Research
Type of surgery	R	R
Primary outcome	R	R
including patient satisfaction		
Secondary outcomes	0	R
Timelines	0	R
Cost analysis	Ν	R
Complications	R	R
Commitment to longer term	0	R
follow up		
cost analysis	0	0



R= Routine O=optional N=not required

414 Acknowledgments

- 415 This has been through 18 versions and 6 collations prior to open to review on both IUGA
- 416 and ICS websites to allow members 4 weeks to submit comments and recommendations
- 417 which have enabled appropriate revisions.
- 418

¹ Haylen B.T., de Ridder D., Freeman R.M, et al. 2010. An International Urogynecological Association (IUGA)/ International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecology J 21:, 5-26. & NeuroUrol Urodyn 29:4-20

² Haylen B.T, Freeman R.M, Swift S et al. 2011. An International Urogynecological Association (IUGA)/ International Continence Society (ICS) joint terminology and classification of the complications related directly to the insertion of prostheses (meshes, implants, tapes) & grafts in female pelvic floor surgery. Int Urogynecol J, 22:3-15. & Neurourol Urodyn 30:2-12

³ Haylen B.T, Freeman R.M, Lee J.et al. 2012 in press. An International urogynecological Association (IUGA)/ International Continence Society (ICS) joint terminology and classification of the complications related to native tissue female pelvic floor surgery. Int Urogynecol J in press NeuroUrol Urodyn

⁴ <u>http://oxforddictionaries.com/definition/outcome</u>

⁵ Abrams P, Andersson KE, Birder L, et al. 2010. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. <u>Neurourol Urodyn.</u>;29(1):213-40

⁶ Lose G, Fantl JA, Victor A et al 1998. Outcome measures for research in adult women with symptoms of lower urinary tract dysfunction. Neurourol Urodyn;17(3):255-62

⁷ Olsen A, Smith V, Bergstrom J, et al. 1997. Epidemiology of surgically managed pelvic organ prolapse and urinary incontinence. Obstetrics & Gynecology. 89(4):501-506.

⁸ Denman M, Gregory W, Boyles S, Smith V, Edwards R, Clark A. 2008. Reoperation rate 10 years after surgically managed pelvic organ prolapse and urinary incontinence. Am J Obstet Gynecol 198:555

⁹ Kapoor DS, Freeman RM. Reoperation rate following prolapse surgery. 2009. Am J Obstet Gynecol. 200(2):e15; author reply e15.

¹⁰ Diwadkar GB, Barber MD, Feiner B, et al 2009. Complications and reoperation rates following surgical repair for apical vaginal prolapse: a meta-analysis. Obstet Gynecol, 113:3670-73

¹¹ Kapoor DS, Nemcova M, Pantaziz K, Brockman P, Bomberi L, Freeman R. 2010. Re-operation rate for traditional anterior repair: analysis of 207 cases with a median 4 year follow up Int J Urogynecol J Pelvic floor dysfunct; 21(1):27-31

¹² Miedel A, Tegerstedt G, et al.2008. A 5-year prospective follow-up study of vaginal surgery for pelvic organ prolapse. Int Urogynecol J Pelvic Floor Dysfunct. ;19(12):1593-601. Epub 2008 Aug 12.

¹³Weber AM, Walters MD, Piedmonte MR, Ballard LA. 2001. Anterior colporrhaphy: a randomized trial of three surgical techniques. Am J Obstet Gynecol; 185:1299–1304

¹⁴ Chmielewski L, Walters MD, Weber AM, Barber MD. Reanalysis of a randomized trial of three techniques of anterior colporrhaphy using clinically relevant definitions of success. Am J Obstet Gynecol 2011, Mar 22 epub ahead of press

¹⁵ Maher, C., Baessler, K., Glazener, C., Adams, E. and Hagen, S. (2008), Surgical management of pelvic organ prolapse in women: A short version Cochrane review. Neurourology and Urodynamics, 27: 3–12. doi: 10.1002/nau.20542

¹⁶Jia X, Glazener C, Mowatt G, et al . Systematic review of the efficacy and safety of using mesh or grafts in surgery for anterior and/or posterior vaginal wall prolapse. ://www.nice.org.uk/guidance/index.jsp?action=download&o=39669.http;

¹⁷ Jia, X., Glazener, C., Mowatt, G., MacLennan, G., Bain, C., Fraser, C. and Burr, J. (2008), Efficacy and safety of using mesh or grafts in surgery for anterior and/or posterior vaginal wall prolapse: systematic review and meta-analysis. BJOG: An International Journal of Obstetrics & Gynaecology, 115: 1350–1361.

¹⁸ <u>http://www.consort-statement.org/consort-statement/</u>

¹⁹ Stroup DF, Berlin JA, Morton SC, et al for the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) Group Meta-analysis of Observational Studies in Epidemiology. A Proposal for Reporting. JAMA. 2000;283:2008-2012

²⁰ <u>http://www.stard-statement.org/</u>

²¹ Hullfish KL, Bovbjerg VE, Gibson J, Steers WD (2002) Patient-centered goals for pelvic floor dysfunction surgery: what is success, and is it achieved? Am J Obstet Gynecol 187:88–92

²² Hullfish KL, Bovbjerg VE, Steers WD (2004) Patient-centered goals for pelvic floor dysfunction surgery: Long-term followup.Am J Obstet Gynecol 191:201–205.

²³ Srikrishna, S., Robinson, D., Cardozo, L. and Cartwright, R. Experiences and expectations of women with urogenital prolapse: a quantitative and qualitative exploration. BJOG 2008; 115: 1362– 1368

²⁴ Srikrishna S, Robinson D, Cardozo L. A longitudinal study of patient and surgeon goal achievement
 2 years after surgery following pelvic floor dysfunction surgery. <u>BJOG.</u> 2010;117(12):1504-11.

²⁵ Doran, George T. "There's a S.M.A.R.T. way to write management's goals and objectives." Management Review, Nov 1981, Volume 70 Issue 11.

²⁶ <u>http://www.iciq.net/</u>

²⁷ Hall AF, Theofrastous JP, Cundiff GC, Harris RL, Hamilton LF, Swift SE, Bump RC. Interobserver and intraobserver reliability of the proposed International Continence Society, Society of Gynecologic Surgeons, and American Urogynecologic Society pelvic organ prolapse classification system. Am J Obstet Gynecol 1996; 175: 1467-1469.

²⁸ Parekh M, Swift S, Lemos N, Iskander M, Freeman R, Arunkalaivanan A, Martan A, Sorinola S, Rizk D, Halaska M, Surkont G, Medina C, Conceicao JC, Korte J. Multicenter inter-examiner agreement trial for the validation of simplified POPQ system. Inter Urogynecol J 2011; DOI: 10.1007/s00192-011-1395-2.

²⁹ Manonai J, Mouritsen L, Palma P, Contreras-Ortiz O, Korte JF, Swift S. The inter-system association between the simplified pelvic organ prolapse quantification system (S-POP) and the standard pelvic organ prolapse quantification system (POPQ) in describing pelvic organ prolapse. Inter Urogynecol J 2011; 22: 347-352.

³⁰ Barber M, Brubaker L, Nygaard I, et al Defining Success After Surgery for Pelvic Organ Prolapse. Obstet Gynecol. 2009 114(3): 600–609

³¹ Srikrishna S, Robinson D, Cardozo L. Validation of the Patient Global Impression of Improvement (PGI-I) for urogenital prolapse Int Urogynecol J (2010) 21:523–528.

³² Brubaker L, Shull B. EGGS for patient centred outcomes. Int Urogynecol J Pelvic floor Dysfunction. 2005 16(3):171-3

³³ Bump RC, Maittiason A, Bo K, et al The standardisation of terminology of female organ prolapsed and pelvic floor dysfunction. Am J Obstet and gynecol. 1996 75;10

³⁴ Weber AM, Abrams P, Brubaker L et al . The standardisation of terminology for researchers in female pelvic floor disorders. Int Urogynecol J. 2001; 12:178-186

³⁵ Dindo D, Demartines N, and Clavien P. Classification of Surgical Complications. A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey. Ann Surg. 2004; 240(2): 205–213.

³⁶ The Clavien-Dino Classification of surgical Complication: 5 years experience. Ann Surg 2009; 250(2): 187-196.

38 White GR. Cystocoele. A radical cure by suturing the lateral sulci of vagina to the white line of pelvic fascia. JAMA 1909;LIII(21):1707-1710.

³⁹ Freeman R and Lose G. The great mesh debate. International Urogynecology Journal, 2009; 20 (8): 889-891.